Article info

Original research
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance

Authors

  1. Correspondence to Professor Yong Gao, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; profgaoyong{at}163.com; Professor Yongsheng Chang, Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China; changys{at}tmu.edu.cn; Dr Changhui Liu, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China; liuchanghui{at}gzucm.edu.cn
View Full Text

Citation

Sun N, Shen C, Zhang L, et al
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance

Publication history

  • Received May 10, 2020
  • Revised October 20, 2020
  • Accepted November 8, 2020
  • First published November 30, 2020.
Online issue publication 
October 07, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.